Why Aurinia Pharmaceuticals Stock Soared 12.2% Today
After reporting favorable pricing for its previously disclosed equity offering, shares in Aurinia Pharmaceuticals (NASDAQ: AUPH) rallied 12.2% on Tuesday.
It's been a busy week for Aurinia's investor relations team. On Dec. 4, the company reported positive phase 3 trial results for voclosporin, combined with Roche's CellCept and low-dose corticosteroids, in lupus nephritis patients. The report sent shares skyrocketing 125%.
Image source: Getty Images.
Source Fool.com
